Author Topic: (ECTRIMS) Early Ocrevus use in PPMS slows disability risk, including risk of wheelchair reliance  (Read 18 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8246
  • MS diagnosed 1980
  • Location: Pacific Northwest
Hmm. No sooner has an announcement touting Mayzent (siponimod) as helpful in delaying the need for a wheelchair for persons with SPMS than it turns out that Ocrevus (ocrelizumab) can also help to keep the dreaded wheelchair away--though the claim here is for PPMS. From Multiple Sclerosis New Today (September 17, 2019)--"ECTRIMS 2019:  Early Ocrevus Use in PPMS Slows Risk of Disability, Including Risk of Wheelchair Reliance."


https://multiplesclerosisnewstoday.com/news-posts/2019/09/06/ectrims2019-early-ocrevus-use-slows-disability-ppms-including-wheelchair-dependence/



MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8246
  • MS diagnosed 1980
  • Location: Pacific Northwest
A more comprehensive overview of some of the Ocrevus material presented at the ECTRIMS conference--again, from Multiple Sclerosis News Today (September 19). The spokespeople are drug company representatives.  There have been 7 PML cases so far, according to the article, but they are careful to point out these were all "carryover cases":


http://bit.ly/2kmpBr4
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
77 Views
Last post March 25, 2016, 06:13:56 am
by agate
0 Replies
54 Views
Last post September 18, 2016, 09:56:46 am
by agate
1 Replies
83 Views
Last post December 07, 2016, 03:02:57 pm
by agate
0 Replies
69 Views
Last post January 26, 2018, 09:46:57 pm
by agate
2 Replies
33 Views
Last post February 15, 2019, 09:40:45 pm
by agate